Ligand Pharmaceuticals
LGND
LGND
256 hedge funds and large institutions have $2.61B invested in Ligand Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 111 increasing their positions, 95 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
13% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 30
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
67% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $36.3M
Holders
256
Holding in Top 10
5
Calls
$11.9M
Puts
$36.3M
Top Buyers
| 1 | +$277M | |
| 2 | +$68.1M | |
| 3 | +$54.4M | |
| 4 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$11.3M |
| 5 |
Renaissance Technologies
New York
|
+$10.7M |
Top Sellers
| 1 | -$53.4M | |
| 2 | -$31.2M | |
| 3 | -$30M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25.8M |
| 5 |
KI
Kalmar Investments
Greenville,
Delaware
|
-$18.1M |